Skip to main content
Clinical Trials/NCT03041896
NCT03041896
Completed
Not Applicable

Retrospective Evaluation of the Clinical and Radiographic Performance of Coflex® Interlaminer Technology Versus Decompression With or Without Fusion.

Paradigm Spine0 sites5,050 target enrollmentJuly 2016
ConditionsSpinal Stenosis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Spinal Stenosis
Sponsor
Paradigm Spine
Enrollment
5050
Primary Endpoint
Overall Duration of Follow-up Care to Evaluate Overall Effectiveness of the Use of the Coflex® Interlaminer Technology
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

To evaluate clinical, radiologic and patient-reported outcomes who have been treated 1 or 2 levels with the coflex® Interlaminar Technology or decompression with or without fusion.

Detailed Description

The coflex® Interlaminar Technology - manufactured by Paradigm Spine - is intended for use as a permanent implant between the lamina of 1 or 2 lumbar motion segments in the treatment of moderate to severe lumbar spinal stenosis. The device is specifically designed to provide stabilization without fusion in cases of stenosis with or without facet joint hypertrophy, subarticular recess stenosis or foraminal stenosis. It is restricted for use to one or two levels in the region of L1 - L5. The height of the neuroforamen is maintained and the facet joints will be relieved. By this a further destruction is prevented. Unlike conventional stabilization methods as for example spinal fusion, the function of the segment will be maintained and adjacent structures will be effectively protected. Possible risks, which could occur after implantation of the coflex® Interlaminar Technology are breakage of the implant, displacement of the implant, pain which is caused by the implant, infections, bleedings and hematoma. The benefit of the study lies in the fact that first-time retrospective data is raised for potential improvement regarding therapy of lumbar back pain with the treatment of the lumbar spinal stenosis, which, in the future, can lead to an improvement of the therapy. In this study, Paradigm Spine will retrospectively collect clinical and radiographic data for patients treated with the coflex® Interlaminar Technology during normal conditions of use. This data will provide evidence to support publications and marketing.

Registry
clinicaltrials.gov
Start Date
July 2016
End Date
August 2018
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Paradigm Spine
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients must meet the criteria specified in the device labeling including radiographic confirmation of at least moderate lumbar stenosis, which narrows the central spinal canal at one or two contiguous levels from L1-L5 that require surgical decompression.

Exclusion Criteria

  • There are no exclusion criteria's for this study.

Outcomes

Primary Outcomes

Overall Duration of Follow-up Care to Evaluate Overall Effectiveness of the Use of the Coflex® Interlaminer Technology

Time Frame: Study Duration Up to 6 months for data collection

To assess the overall duration of follow-up care to evaluate overall effectiveness of the use of the coflex® Interlaminer Technology verses decompression.

Overall Incidence of Secondary Surgical Interventions Post Surgeries.

Time Frame: Study Duration up to 6 months data

To analyze the incidence of secondary surgical interventions to evaluate overall effectiveness of the use of the coflex® Interlaminer Technology vs. decompression.

Secondary Outcomes

  • The Secondary Objectives Include Measuring and Comparing Clinical, Radiologic, and Patient Reported Outcomes at Baseline, Interim and/or Final Follow-up Visits.(Study Duration Up to 6 months for data collection)

Similar Trials